Company Urges Shareholders to Follow ISS’ Recommendation and Vote the WHITE Proxy Card BURLINGTON, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (“Neuphoria” or the “Company”) (NASDAQ: NEUP), a clinical-stage biotechnology company dedicated to developing therapies that
Neuphoria Will Continue its Well-Planned Strategic Alternatives Review, Which has Garnered Significant Positive Interest Urges Stockholders to Vote “FOR” BOTH of Neuphoria’s Nominees on the WHITE Proxy Card BURLINGTON, Mass., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc.
BURLINGTON, Mass., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (“Neuphoria” or the “Company”) (NASDAQ: NEUP), a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders, today issued
Files Definitive Proxy Statement for 2025 Annual Meeting of Stockholders Urges Stockholders to Vote “FOR” BOTH Neuphoria Therapeutics Nominees on WHITE Proxy Card BURLINGTON, Mass., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (“Neuphoria” or the “Company”), a clinical-stage
Confirms Receipt of Unsolicited Indication of Interest and Director Nominations from Lynx1 Master Fund LP No Stockholder Action Required at This Time BURLINGTON, Mass., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (“Neuphoria” or the “Company”) (Nasdaq: NEUP), a clinical-stage
BURLINGTON, Mass., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (“Neuphoria” or the “Company”) (Nasdaq: NEUP), a clinical-stage biotechnology company developing impactful treatments for neuropsychiatric disorders, today announced that its Board of Directors (the “Board”) has
AFFIRM-1 trial did not meet primary endpoint or secondary endpoints Company to conduct strategic review of portfolio and business operations BURLINGTON, Mass., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (Nasdaq: NEUP) (“Neuphoria” or the “Company”), a clinical-stage biotechnology
Last patient last visit (LPLV) milestone in AFFIRM-1 Phase 3 trial of BNC-210 in social anxiety disorder (SAD) achieved; topline readout anticipated in early Q4 2025 Cash runway extended through fiscal Q2 2027 BURLINGTON, Mass., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc.
Topline data anticipated in early Q4 2025 BURLINGTON, Mass., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (Nasdaq: NEUP) (“Neuphoria” or the “Company”), a clinical-stage biotechnology company developing impactful treatments for neuropsychiatric disorders, today announced the
BURLINGTON, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (Nasdaq: NEUP) (“Neuphoria” or the “Company”), a clinical-stage biotechnology company developing impactful treatments for neuropsychiatric disorders, today announced that Spyros Papapetropoulos, M.D., Ph.D., President
